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In this issue of JEM, Umemoto et al. (https:// doi .org/ 10 .1084/ jem .20180421) demonstrate that calcium influx stimulates 
mitochondrial metabolism and initiates proliferation in hematopoietic stem cells (HSCs). Extracellular adenosine, sourced from 
surrounding hematopoietic progenitors, inhibits this calcium influx, thereby suppressing mitochondrial metabolism and promoting 
HSC quiescence. This is the first demonstration that a calcium–mitochondria pathway regulates HSC division.
Ca2+tapulting HSCs into action
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The ability to precisely control hematopoi-
etic stem cell (HSC) quiescence, self-renewal, 
and differentiation is a prerequisite for the 
identification of effective means of expand-
ing clinically relevant multipotent HSCs for 
widespread transplantation purposes. While 
a number of studies have revealed some of 
the key epigenetic and transcriptional reg-
ulators controlling HSC maintenance, the 
essential metabolic regulators of HSC fates 
and their utility in HSC expansion still re-
main poorly understood. Quiescent HSCs 
predominantly reside in perisinusoidal re-
gions of the bone marrow (BM) where the 
oxygen tension is markedly low (Ding et al., 
2012; Spencer et al., 2014). As a consequence, 
local hypoxia has been proposed to maintain 
HSC quiescence and a low metabolic state, 
at least in part through the HIF-1–PDK2/4 
pathway (Simsek et al., 2010; Takubo et al., 
2013). Mitochondria require oxygen to gen-
erate their membrane potential and produce 
ATP, but quiescent HSCs suppress mitochon-
drial metabolism and predominantly rely on 
glycolysis for energy production (Simsek 
et al., 2010). However, quiescent HSCs are 
also found in periarteriolar areas of the BM 
(Kunisaki et al., 2013), where the local oxy-
gen tension is significantly higher compared 
with the perisinusoidal regions (Spencer 
et al., 2014). Furthermore, HSCs cultured 
under normoxic conditions also display 
low mitochondrial metabolic activity (de 
Almeida et al., 2017). Together, these obser-
vations indicate that hypoxia may not be the 
sole cause of low mitochondrial metabolism 
in quiescent HSCs.
In this issue, Umemoto et al. investigates 
the metabolic regulation of HSC fate deci-
sions between quiescence and proliferation. 
Gene expression analyses in quiescent HSCs 
from untreated mice and activated HSCs 
(sampled just before they enter cell divi-
sion) from 5-fluorouracil (5-FU)–treated 
mice were performed to reveal molecular 
mechanisms underpinning the onset of HSC 
division. In addition to enrichment of cell 
cycle–related and pro-growth mTOR and 
glycolysis gene sets, notably, they found a 
strong enrichment of genes associated with 
oxidative phosphorylation. This important 
result focused the study on changes in mi-
tochondrial metabolism that precede HSC 
transition from quiescence to cell cycle re-
entry. The authors found that HSCs display 
significant calcium influx into their cytosol 
and mitochondria and a concomitant in-
crease in mitochondrial potential as a pre-
requisite for cell division in vitro. In their 
in vivo experiments, they used the ability 
of 5-FU to trigger HSC cell cycle reentry 
following depletion of more mature cycling 
hematopoietic cells. Intriguingly, HSCs from 
5-FU–treated mice had elevated levels of 
intracellular calcium and enhanced mito-
chondrial potential before their division. In 
accordance with this, HSCs stimulated with 
thrombopoietin (TPO) and stem cell factor 
(SCF) in vitro also displayed the activation 
of this calcium–mitochondria pathway be-
fore undergoing cell division. The suppres-
sion of extracellular calcium influx into 
HSCs by Nifedipine or Isradipine (blockers 
of L-type voltage-gated Ca2+ channels) abol-
ished the increase of intracellular Ca2+ and 
the resultant mitochondrial activation and 
prolonged the interval between the cell di-
vision through suppressing the expression 
of genes involved in late G1 phase of the cell 
cycle. While HSCs cultured in the absence of 
Ca2+ channel blockers lost their in vivo mul-
tilineage reconstitution potential following 
several divisions in vitro, those treated with 
Nifedipine maintained their undifferenti-
ated immunophenotype and retained their 
stem cell activity upon transplantation. This 
suggests that calcium is a pivotal regulator 
of the balance between HSC quiescence and 
entry into the cell cycle.
In search for mechanisms underlying the 
regulation of the calcium–mitochondria 
pathway in HSCs, Umemoto et al. (2018) dis-
covered that myeloid progenitor cells co-cul-
tured with HSCs suppress the Ca2+ influx 
into HSCs. Intriguingly, this effect is medi-
ated, at least in part, by adenosine produced 
in myeloid progenitors, which activates 
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adenosine A2 receptors expressed by HSCs 
and thereby negatively regulates Ca2+ influx 
into HSCs and consequent mitochondrial 
activation. In their in vivo experiments, the 
authors demonstrated that following 5-FU–
mediated myeloablation, the levels of ade-
nosine drop, coinciding with an activation 
of the Ca2+–mitochondria pathway and HSC 
division. Notably, administration of an ad-
enosine A2 receptor agonist following 5-FU 
treatment suppressed mitochondrial activ-
ity of HSCs and dampened their division. 
Thus, a decrease in extracellular adenosine 
(produced by myeloid progenitors that are 
depleted by 5-FU) within the BM microenvi-
ronment is at least one mechanism through 
which HSCs undergo cell division upon 
myeloablation.
Recent investigations revealed that al-
though quiescent HSCs have reduced mi-
tochondrial respiration compared with 
progenitor cells, their mitochondrial con-
tent is unexpectedly high and mitochondrial 
turnover is low (de Almeida et al., 2017). 
However, why quiescent HSCs would re-
quire high mitochondrial mass and how the 
mitochondrial activity is suppressed (even 
under normoxic conditions) in HSCs re-
mains puzzling. The work by Umemoto et al. 
(2018) suggests that quiescent HSCs sense 
extracellular adenosine from the BM mi-
croenvironment to suppress Ca2+ influx and 
inhibit mitochondrial activation. However, 
high mitochondrial content in quiescent 
HSCs may poise them for rapid induction of 
the oxidative phosphorylation necessary for 
cell cycle reentry. The activities of three key 
energetic mitochondrial dehydrogenases 
(pyruvate dehydrogenase, NAD-isocitrate 
dehydrogenase, and oxoglutarate dehydro-
genase) are stimulated by Ca2+ ions (Denton, 
2009), and this offers a mechanism whereby 
influx of Ca2+ would stimulate mitochon-
drial ATP generation. Thus, in the scenario 
portrayed by the authors, division-inducing 
stimuli such as myeloablation, bleeding, cy-
tokines, or bacterial pathogens induce Ca2+ 
influx and activate ATP production neces-
sary to undergo HSC division. There are, 
however, many outstanding questions that 
merit further investigations. How are Ca2+ 
levels regulated during different phases of 
the cell cycle and between sequential cell di-
visions in HSCs? What are the events down-
stream of the Ca2+–mitochondria pathway 
that determine HSC fate decisions between 
self-renewal and differentiation? Do HSCs 
pump out Ca2+ to sustain quiescence? Fi-
nally, considering the role of the Ca2+–mito-
chondria pathway in HSC division, how does 
Ca2+ influx impact on leukemic transforma-
tion and leukemic stem cell functions?
The paper by Umemoto et al. (2018) re-
inforces an emerging role of adenosine as 
a key extracellular regulator of adult HSC 
quiescence. The authors demonstrate that 
myeloid progenitor cells maintain HSC qui-
escence by producing adenosine. The ec-
tonucleotidase CD73, which converts AMP 
into adenosine, is expressed in several other 
cell types surrounding HSCs. The CD150High 
regulatory T cell (T reg) population, which 
is frequently adjacent to HSCs within their 
niches, promotes HSC quiescence and en-
hances allo-HSC engraftment upon trans-
The role of the adenosine–|Ca2+→mitochondria axis in the regulation of HSC division. Left: Adenosine (ADO) 
through adenosine A2 receptor prevents calcium entry to maintain low mitochondrial membrane potential 
and sustain HSC quiescence. Right: TPO and SCF induce calcium influx in HSCs through L-type voltage-gated 
Ca2+ channel (VGCC), which in turn activates mitochondria, leading to HSC division. Ca2+ influx may also 
regulate multiple other targets, including CaM, calpains, and the PKC family members, to exert its functions 
in HSCs. This figure was created using the Servier Medical Art database (licensed under a Creative Commons 
Attribution 3.0 Unported License).
Adenosine maintains HSC quiescence in vivo. Under physiological condition, T reg cells, myeloid progenitors, 
endothelial cells, and mesenchymal stromal cells express ecto-5′-nucleotidase (CD73), which converts AMP 
to adenosine. Adenosine presence in the BM microenvironment is sensed by adenosine A2 receptor (A2R), 
thereby inhibiting influx of extracellular Ca2+ and promoting HSC quiescence. This figure was created using 
the Servier Medical Art database (licensed under a Creative Commons Attribution 3.0 Unported License).
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plantation (Hirata et al., 2018). These T 
reg cells produce adenosine, which in turn 
activates adenosine A2 receptors (highly 
expressed in HSCs) to promote HSC qui-
escence. CD73 is also highly expressed in 
mesenchymal stromal cells and sinusoidal 
endothelial cells, which are in close contact 
with quiescent HSCs and are essential for 
HSC maintenance (Breitbach et al., 2018). 
Thus, adenosine production may be a more 
general feature of hematopoietic cells and 
the BM microenvironment supporting HSC 
quiescence. Finally, Umemoto et al. (2018) 
indicate that one mechanism of adenosine’s 
action in HSCs is to suppress the Ca2+–mito-
chondria pathway. However, how adenosine 
A2 receptor inhibits Ca2+ influx into HSCs to 
regulate HSC fates remains an open ques-
tion for future investigations.
The authors propose direct links be-
tween elevation of cytosolic Ca2+, elevation 
of mitochondrial Ca2+, and mitochondrial 
ATP production, but important questions 
remain unanswered. First, a recent paper 
by Luchsinger et al. (2016) indicated that 
Mitofusin 2 regulates HSC maintenance by 
tethering of mitochondria to the endoplas-
mic reticulum and thereby promoting buff-
ering of intracellular Ca2+. The interplay 
between the calcium–mitochondria path-
way described by Umemoto et al. (2018) and 
the intracellular Ca2+ buffering described by 
Luchsinger et al. (2016) and how it impacts 
on HSC division merit further investiga-
tions. The second question is whether the 
transfer of Ca2+ is indeed direct and, if so, 
through what channels. Mitochondrial Ca2+ 
has been reported to respond optimally to 
pulsatile, rather than sustained, cytosolic 
Ca2+ (Hajnóczky et al., 1995), and this sug-
gests that the sustained influx of extracellu-
lar Ca2+ described by Umemoto et al. (2018) 
would be unlikely to result in transfer of the 
Ca2+ signal to the mitochondrion. Another 
outstanding question is what role other 
Ca2+-activated pathways play in the promo-
tion of proliferation in HSCs. Ca2+ has long 
been known to drive proliferation in many 
cell types through direct activation of calm-
odulin (CaM), which promotes both G1/S 
and G2/M transition through several mech-
anisms, including Ca2+-dependent activa-
tion of the cyclin/cyclin-dependent kinase 
complexes. Calpains and members of the 
protein kinase C (PKC) family are also reg-
ulated by Ca2+, and thus the possibility for 
multiple Ca2+-activated signaling pathways 
to impact upon HSC proliferation exists.
The key future application of the study 
by Umemoto et al. (2018) is the expansion 
of HSCs for transplantation purposes. HSC 
transplantation (HSCT) often remains the 
only curative therapy in blood malignancies 
or severe immunodeficiencies. However, 
the shortage of histocompatible donors and 
limited numbers of HSCs that can be ob-
tained from their sources (e.g., umbilical 
cord blood) often limit the widespread ap-
plications of HSCT. Therefore, the ex vivo 
expansion of clinically relevant HSCs is an 
unmet clinical need. The current study indi-
cates that in vitro HSC culture in the pres-
ence of Ca2+ channel blocker, adenosine, or 
adenosine A2 receptor agonist allows for 
HSC divisions while maintaining their un-
differentiated state. This discovery offers 
an exciting possibility that these agents may 
synergize with currently applicable HSC ex-
pansion approaches (e.g., those using an aryl 
hydrocarbon receptor antagonist StemRege-
nin-1 [Wagner et al., 2016] or the pyrimido-
indole derivative UM171 [Fares et al., 2014]) 
to provide unprecedented numbers of clini-
cally relevant multipotent HSCs. Equally ex-
citing is the prospect of modulating cellular 
Ca2+ levels to either protect HSCs from my-
eloablative chemotherapies or expand them 
in vivo following allogeneic HSCT.
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